Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 4/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6886667 | 0.83 | ADORA1 (0.60) | MERTKADORA1ADORA2AADORA2BAXL | |
| SCHEMBL6884017 | 0.83 | ADORA1 (0.60) | MERTKADORA1ADORA2AADORA2BAXL | |
| SCHEMBL1642532 | 0.82 | ACACB (0.49) | MAPK6DRD2DRD3 | |
| SCHEMBL1642534 | 0.82 | ACACB (0.49) | MAPK6DRD2DRD3 | |
| SCHEMBL6886534 | 0.81 | KDM4E (0.56) | MERTKADORA1ADORA2AADORA2BHDAC1 | |
| SCHEMBL6885645 | 0.80 | GRM5 (0.48) | MERTKADORA1ADORA2AADORA2BHDAC1 | |
| SCHEMBL13062703 | 0.80 | HDAC1 (0.56) | ADORA1ADORA2AADORA2BHDAC1MAPT | |
| SCHEMBL6887143 | 0.80 | KDM4E (0.59) | MERTKADORA1HDAC1AXLTYRO3 | |
| Hydrochloric Acid SCHEMBL3776468 | 0.79 | HDAC1 (0.55) | ADORA1ADORA2AADORA2BHDAC1MAPT | |
| SCHEMBL6886647 | 0.78 | ADORA1 (0.51) | MERTKADORA1ADORA2AADORA2BAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389536-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | GRM5, GRM1, GRM2 | MERTK 1646/4885ADORA1 161/4885ADORA2A 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.